Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mylan Bertek Pharmaceuticals Inc.

Division of Mylan NV

Latest From Mylan Bertek Pharmaceuticals Inc.

Can an Overthrown King Help Mylan?

Mylan, one of the nation's top three generics companies, is offering to buy King Pharmaceuticals for $3.7 billion in a stock swap in order to boost its efforts in the branded pharmaceutical business. But the controversial proposal and reaction to it raises interesting questions about business models in specialty pharma, a concept that has, many ways, taken over the small-company pharma world.
Strategy Business Strategies

Mylan's New Focus

For most of the 1990s, Mylan Laboratories was the dominant US generics manufacturer both in terms of financial performance and creative competitive strategies. But it seems to have lost its way a bit and is struggling to regain its competitive edge in an industry that no longer reflects the world it grew up in. Revenues grew a sluggish 7% to $846 million in 2001, in part because efforts to diversify into proprietary drugs haven't met goals. In June, two top executives left, both of whom had been there only a short time.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Bertek Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Mylan NV
  • Senior Management
  • Michael Marquard, Pres.
  • Contact Info
  • Mylan Bertek Pharmaceuticals Inc.
    Phone: (919) 991-9800
    P.O. Box 14149
    Research Triangle Pk., NC 27709-4149